Cambrex completes pilot plant expansion at its High Point, NC facility

16 May 2018

Site's reactor capacity is increased by 30%.

Cambrex has completed a pilot plant expansion at its High Point, NC facility with the installation and commissioning of a fourth reactor suite, increasing the site's reactor capacity by around 30%.

Cambrex completes pilot plant expansion at its High Point, NC facility

The new 400-sq ft suite includes two 2,000-L glass-lined reactors and a 0.6 m2 Hastelloy C22 filter dryer, allowing the manufacture of batch sizes typically 10-100 kg under cGMP conditions for clinical-phase projects.

The High Point site has also completed and implemented an upgrade of its analytical chromatography data systems for QC and analytical R&D to new, Empower 3 software. Empower brings enhanced capability, integrity and compliance to the site’s analytical systems, in line with the increasingly stringent demands of the FDA and EMA among other agencies.

In a further announcement, Cambrex has reported that structural steelwork and foundations are now in place for a new $24 million facility at its Charles City, Iowa plant, for the manufacture of highly potent APIs (HPAPIs).

The 4,500-sq ft production area will operate to an occupational exposure limit (OEL) down to 0.1µg/m³ and will have a total reactor capacity of 2,200 gallons, consisting of a range of 200, 500 and 1,000 gallon glass and Hastelloy vessels to manufacture batches from 50 to 300 kg.

The project will also see the reconfiguration of the existing small-scale manufacturing area, providing a single high containment building to support early-stage development and manufacturing, providing flexibility across a broad range of scale. The facility is expected to be operational in the first half of 2019.

“Both of these US investments will enhance Cambrex’s cGMP capabilities and offer our customers expanded technologies and services,” commented Shawn Cavanagh, COO of Cambrex. He added: “We will continue to strategically invest across our global network of sites at all scales, from clinical through to commercial, to address customer demands and market requirements.”

Cambrex recently announced that it had also completed the construction and validation of a new 11,000 sq. ft. analytical laboratory at its High Point facility, as well as completing the installation of multiple continuous flow reactor platforms.

Read More

Related news

Compact serialization-ready manual workstation

Compact serialization-ready manual workstation

11 Aug 2018

A cost-effective and space-saving solution for serializing cartons and performing multi-level aggregation on cases and pallets.

Read more 
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

8 Aug 2018

Company moves away from manual processing in favour of automated, scalable platforms.

Read more 
BASF receives award for its portfolio of natural cosmetic ingredients

BASF receives award for its portfolio of natural cosmetic ingredients

7 Aug 2018

Company recognised for its innovation and continual delivery of new natural ingredients.

Read more 
Extended distribution agreement enables customers to continuously improve their bioprocesses

Extended distribution agreement enables customers to continuously improve their bioprocesses

6 Aug 2018

Agreement includes Pall's next-generation Kaneka KanCapA 3G sorbent for the primary capture of mAbs from clarified cell culture.

Read more 
A new era for migraine patients

A new era for migraine patients

6 Aug 2018

EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

Read more 
Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island

Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island

3 Aug 2018

The plant will be first-of-its-kind in the US.

Read more 
Croda invests in SiSaf’s novel bio-courier technology

Croda invests in SiSaf’s novel bio-courier technology

3 Aug 2018

ProSilic will give Croda’s customers access to the next generation of targeted and controlled drug delivery.

Read more 
Breast cancer device receives FDA approval

Breast cancer device receives FDA approval

3 Aug 2018

The first non-radioactive, dual-tracer for sentinel lymph node biopsy approved in the US.

Read more 
Building contingency plans for an ambiguous post-Brexit market

Building contingency plans for an ambiguous post-Brexit market

31 Jul 2018

One company's positive approach to Brexit preparations, despite the lack of definition.

Read more 
Cherwell publishes guide on environmental monitoring processes and validation

Cherwell publishes guide on environmental monitoring processes and validation

31 Jul 2018

Supporting EM programs in preparation for proposed EU GMP Annex 1 changes.

Read more